{"result": {"id": "7621897e-e7e0-4547-ae0f-22c8dd7cfeb7", "choices": [{"finish_reason": "stop", "index": 0, "logprobs": null, "message": {"content": "(\"entity\"<|>ATHEROSCLEROSIS<|>ORGANIZATION<|>Journal where a study on cardiovascular disease was published\")\n##\n(\"entity\"<|>BEMPEDOIC ACID<|>ORGANIZATION<|>Pharmaceutical agent studied in the CLEAR Wisdom Randomized Clinical Trial\")\n##\n(\"entity\"<|>CETP INHIBITOR OBICETRAPIB<|>ORGANIZATION<|>Drug studied in combination with statins for lipid lowering effects\")\n##\n(\"entity\"<|>MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN INHIBITOR<|>ORGANIZATION<|>Therapeutic agent studied for homozygous familial hypercholesterolaemia\")\n##\n(\"entity\"<|>PCSK9 INHIBITOR MK-0616<|>ORGANIZATION<|>Oral medication evaluated in a phase 2b randomized trial\")\n##\n(\"entity\"<|>EVINACUMAB<|>ORGANIZATION<|>Monoclonal antibody treatment for homozygous familial hypercholesterolemia\")\n##\n(\"entity\"<|>VOLANESORSEN<|>ORGANIZATION<|>Drug studied for triglyceride reduction in familial chylomicronemia syndrome\")\n##\n(\"entity\"<|>LIPOPROTEIN(A)<|>ORGANIZATION<|>Lipoprotein particle targeted by emerging therapeutics\")\n##\n(\"entity\"<|>CRISPR BASE EDITING<|>ORGANIZATION<|>Gene editing technology used to modify PCSK9 in primates\")\n##\n(\"relationship\"<|>BEMPEDOIC ACID<|>CLEAR WISDOM RANDOMIZED CLINICAL TRIAL<|>Bempedoic acid was the intervention studied in the CLEAR Wisdom trial<|>9)\n##\n(\"relationship\"<|>CETP INHIBITOR OBICETRAPIB<|>NAT MED<|>Study of CETP inhibitor obicetrapib was published in Nature Medicine<|>8)\n##\n(\"relationship\"<|>MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN INHIBITOR<|>LANCET<|>Study of MTP inhibitor was published in The Lancet<|>8)\n##\n(\"relationship\"<|>PCSK9 INHIBITOR MK-0616<|>J AM COLL CARDIOL<|>Trial of MK-0616 was published in JACC<|>8)\n##\n(\"relationship\"<|>EVINACUMAB<|>N ENGL J MED<|>Study of evinacumab was published in NEJM<|>8)\n##\n(\"relationship\"<|>VOLANESORSEN<|>N ENGL J MED<|>Study of volanesorsen was published in NEJM<|>8)\n##\n(\"relationship\"<|>LIPOPROTEIN(A)<|>AM J PREV CARDIOL<|>Review of lipoprotein(a) therapeutics was published in AJPC<|>8)\n##\n(\"relationship\"<|>CRISPR BASE EDITING<|>NATURE<|>CRISPR study was published in Nature<|>8)\n<|COMPLETE|>", "refusal": null, "role": "assistant", "annotations": null, "audio": null, "function_call": null, "tool_calls": null}}], "created": 1751559314, "model": "deepseek-chat", "object": "chat.completion", "service_tier": null, "system_fingerprint": "fp_8802369eaa_prod0623_fp8_kvcache", "usage": {"completion_tokens": 688, "prompt_tokens": 5244, "total_tokens": 5932, "completion_tokens_details": null, "prompt_tokens_details": {"audio_tokens": null, "cached_tokens": 5184}, "prompt_cache_hit_tokens": 5184, "prompt_cache_miss_tokens": 60}}, "input": {"messages": [{"content": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: J]. Atherosclerosis,  2021, 325:99?109. DOI: 10.1016/j.atherosclerosis.2021.03.039.\n[60]      Goldberg AC, Leiter LA, Stroes E, et al. Effect of bempedoic acid vs  placebo  added to  maximally tolerated  statins  on low?density  lipoprotein  cholesterol  in  patients  at  high risk   for    cardiovascular   disease:   the    CLEAR    Wisdom Randomized    Clinical    Trial [J].    JAMA,    2019,     322 (18): 1780?1788. DOI: 10.1001/jama.2019.16585.\n[61]      Nicholls SJ, Ditmarsch M, Kastelein JJ, et al. Lipid lowering effects  of the  CETP  inhibitor  obicetrapib  in  combination with high?intensity statins: a randomized phase 2 trial[J]. Nat    Med,     2022,    28 (8):    1672?1678.    DOI:     10.1038/ s41591?022?01936?7.\n[62]       Cuchel  M,  Meagher  EA,  du  Toit  Theron  H,  et al.  Efficacy and  safety  of  a  microsomal  triglyceride  transfer  protein inhibitor      in      patients      with      homozygous      familial hypercholesterolaemia: a single?arm, open?label, phase  3 study[J].  Lancet,  2013,  381 (9860): 40?46.  DOI:  10.1016/ S0140?6736 (12)61731?0.\n[63]       Ballantyne   CM,    Banka   P,    Mendez   G,    et al.    Phase   2b randomized trial of the oral PCSK9 inhibitor MK?0616 [J]. J Am Coll Cardiol, 2023, 81 (16):1553?1564. DOI: 10.1016/ j.jacc.2023.02.018.\n[64]      Raal  FJ,  Rosenson  RS, Reeskamp LF, et al.  Evinacumab for homozygous  familial  hypercholesterolemia[J].   N   Engl  J Med,       2020,       383 (8):       711?720.       DOI:       10.1056/ NEJMoa2004215.\n[65]      Witztum  JL,  Gaudet  D,  Freedman  SD,  et al.  Volanesorsen and    triglyceride    levels    in     familial    chylomicronemia syndrome[J].  N  Engl  J  Med,  2019,  381 (6): 531?542.  DOI: 10. 1056/NEJMoa1715944.\n[66]      Kaur G, Abdelrahman K, Berman AN, et al. Lipoprotein(a): emerging insights and therapeutics[J]. Am J Prev Cardiol, 2024, 18:100641. DOI: 10.1016/j.ajpc.2024.100641.\n[67]      Brandts   J,   Ray   KK.   Novel   and   future   lipid?modulating therapies for the prevention of cardiovascular disease[J]. Nat  Rev  Cardiol,  2023,  20 (9): 600?616.  DOI:   10.1038/ s41569?023?00860?8.\n[68]       Musunuru  K,  Chadwick  AC,  Mizoguchi  T,  et al.   In  vivo CRISPR base editing of PCSK9 durably lowers cholesterol in  primates[J].   Nature,  2021,  593 (7859): 429?434.  DOI: 10.1038/s41586?021?03534?y.\n######################\nOutput:", "role": "user"}, {"role": "assistant", "content": "(\"entity\"<|>CLEAR WISDOM RANDOMIZED CLINICAL TRIAL<|>EVENT<|>A clinical trial evaluating the effect of bempedoic acid vs placebo on LDL cholesterol in high-risk cardiovascular patients\")\n##\n(\"entity\"<|>GOLDBERG AC<|>PERSON<|>Researcher involved in the CLEAR Wisdom Randomized Clinical Trial\")\n##\n(\"entity\"<|>LEITER LA<|>PERSON<|>Researcher involved in the CLEAR Wisdom Randomized Clinical Trial\")\n##\n(\"entity\"<|>STROES E<|>PERSON<|>Researcher involved in the CLEAR Wisdom Randomized Clinical Trial\")\n##\n(\"entity\"<|>JAMA<|>ORGANIZATION<|>Journal where the CLEAR Wisdom Randomized Clinical Trial was published\")\n##\n(\"entity\"<|>NICHOLLS SJ<|>PERSON<|>Researcher involved in the phase 2 trial of CETP inhibitor obicetrapib\")\n##\n(\"entity\"<|>DITMARSCH M<|>PERSON<|>Researcher involved in the phase 2 trial of CETP inhibitor obicetrapib\")\n##\n(\"entity\"<|>KASTELEIN JJ<|>PERSON<|>Researcher involved in the phase 2 trial of CETP inhibitor obicetrapib\")\n##\n(\"entity\"<|>NAT MED<|>ORGANIZATION<|>Journal where the phase 2 trial of CETP inhibitor obicetrapib was published\")\n##\n(\"entity\"<|>CUCHEL M<|>PERSON<|>Researcher involved in the phase 3 study of microsomal triglyceride transfer protein inhibitor\")\n##\n(\"entity\"<|>MEAGHER EA<|>PERSON<|>Researcher involved in the phase 3 study of microsomal triglyceride transfer protein inhibitor\")\n##\n(\"entity\"<|>DU TOIT THERON H<|>PERSON<|>Researcher involved in the phase 3 study of microsomal triglyceride transfer protein inhibitor\")\n##\n(\"entity\"<|>LANCET<|>ORGANIZATION<|>Journal where the phase 3 study of microsomal triglyceride transfer protein inhibitor was published\")\n##\n(\"entity\"<|>BALLANTYNE CM<|>PERSON<|>Researcher involved in the phase 2b trial of oral PCSK9 inhibitor MK-0616\")\n##\n(\"entity\"<|>BANKA P<|>PERSON<|>Researcher involved in the phase 2b trial of oral PCSK9 inhibitor MK-0616\")\n##\n(\"entity\"<|>MENDEZ G<|>PERSON<|>Researcher involved in the phase 2b trial of oral PCSK9 inhibitor MK-0616\")\n##\n(\"entity\"<|>J AM COLL CARDIOL<|>ORGANIZATION<|>Journal where the phase 2b trial of oral PCSK9 inhibitor MK-0616 was published\")\n##\n(\"entity\"<|>RAAL FJ<|>PERSON<|>Researcher involved in the study of evinacumab for homozygous familial hypercholesterolemia\")\n##\n(\"entity\"<|>ROSENSON RS<|>PERSON<|>Researcher involved in the study of evinacumab for homozygous familial hypercholesterolemia\")\n##\n(\"entity\"<|>REESKAMP LF<|>PERSON<|>Researcher involved in the study of evinacumab for homozygous familial hypercholesterolemia\")\n##\n(\"entity\"<|>N ENGL J MED<|>ORGANIZATION<|>Journal where the study of evinacumab for homozygous familial hypercholesterolemia was published\")\n##\n(\"entity\"<|>WITZTUM JL<|>PERSON<|>Researcher involved in the study of volanesorsen and triglyceride levels in familial chylomicronemia syndrome\")\n##\n(\"entity\"<|>GAUDET D<|>PERSON<|>Researcher involved in the study of volanesorsen and triglyceride levels in familial chylomicronemia syndrome\")\n##\n(\"entity\"<|>FREEDMAN SD<|>PERSON<|>Researcher involved in the study of volanesorsen and triglyceride levels in familial chylomicronemia syndrome\")\n##\n(\"entity\"<|>N ENGL J MED<|>ORGANIZATION<|>Journal where the study of volanesorsen and triglyceride levels in familial chylomicronemia syndrome was published\")\n##\n(\"entity\"<|>KAUR G<|>PERSON<|>Researcher involved in the study of lipoprotein(a) and emerging therapeutics\")\n##\n(\"entity\"<|>ABDELRAHMAN K<|>PERSON<|>Researcher involved in the study of lipoprotein(a) and emerging therapeutics\")\n##\n(\"entity\"<|>BERMAN AN<|>PERSON<|>Researcher involved in the study of lipoprotein(a) and emerging therapeutics\")\n##\n(\"entity\"<|>AM J PREV CARDIOL<|>ORGANIZATION<|>Journal where the study of lipoprotein(a) and emerging therapeutics was published\")\n##\n(\"entity\"<|>BRANDTS J<|>PERSON<|>Researcher involved in the review of novel lipid-modulating therapies for cardiovascular disease prevention\")\n##\n(\"entity\"<|>RAY KK<|>PERSON<|>Researcher involved in the review of novel lipid-modulating therapies for cardiovascular disease prevention\")\n##\n(\"entity\"<|>NAT REV CARDIOL<|>ORGANIZATION<|>Journal where the review of novel lipid-modulating therapies for cardiovascular disease prevention was published\")\n##\n(\"entity\"<|>MUSUNURU K<|>PERSON<|>Researcher involved in the study of CRISPR base editing of PCSK9 in primates\")\n##\n(\"entity\"<|>CHADWICK AC<|>PERSON<|>Researcher involved in the study of CRISPR base editing of PCSK9 in primates\")\n##\n(\"entity\"<|>MIZOGUCHI T<|>PERSON<|>Researcher involved in the study of CRISPR base editing of PCSK9 in primates\")\n##\n(\"entity\"<|>NATURE<|>ORGANIZATION<|>Journal where the study of CRISPR base editing of PCSK9 in primates was published\")\n##\n(\"relationship\"<|>GOLDBERG AC<|>CLEAR WISDOM RANDOMIZED CLINICAL TRIAL<|>Goldberg AC was a researcher in the CLEAR Wisdom Randomized Clinical Trial<|>8)\n##\n(\"relationship\"<|>LEITER LA<|>CLEAR WISDOM RANDOMIZED CLINICAL TRIAL<|>Leiter LA was a researcher in the CLEAR Wisdom Randomized Clinical Trial<|>8)\n##\n(\"relationship\"<|>STROES E<|>CLEAR WISDOM RANDOMIZED CLINICAL TRIAL<|>Stroes E was a researcher in the CLEAR Wisdom Randomized Clinical Trial<|>8)\n##\n(\"relationship\"<|>CLEAR WISDOM RANDOMIZED CLINICAL TRIAL<|>JAMA<|>The CLEAR Wisdom Randomized Clinical Trial was published in JAMA<|>7)\n##\n(\"relationship\"<|>NICHOLLS SJ<|>NAT MED<|>Nicholls SJ was a researcher in a study published in Nat Med<|>8)\n##\n(\"relationship\"<|>DITMARSCH M<|>NAT MED<|>Ditmarsch M was a researcher in a study published in Nat Med<|>8)\n##\n(\"relationship\"<|>KASTELEIN JJ<|>NAT MED<|>Kastelein JJ was a researcher in a study published in Nat Med<|>8)\n##\n(\"relationship\"<|>CUCHEL M<|>LANCET<|>Cuchel M was a researcher in a study published in Lancet<|>8)\n##\n(\"relationship\"<|>MEAGHER EA<|>LANCET<|>Meagher EA was a researcher in a study published in Lancet<|>8)\n##\n(\"relationship\"<|>DU TOIT THERON H<|>LANCET<|>Du Toit Theron H was a researcher in a study published in Lancet<|>8)\n##\n(\"relationship\"<|>BALLANTYNE CM<|>J AM COLL CARDIOL<|>Ballantyne CM was a researcher in a study published in J Am Coll Cardiol<|>8)\n##\n(\"relationship\"<|>BANKA P<|>J AM COLL CARDIOL<|>Banka P was a researcher in a study published in J Am Coll Cardiol<|>8)\n##\n(\"relationship\"<|>MENDEZ G<|>J AM COLL CARDIOL<|>Mendez G was a researcher in a study published in J Am Coll Cardiol<|>8)\n##\n(\"relationship\"<|>RAAL FJ<|>N ENGL J MED<|>Raal FJ was a researcher in a study published in N Engl J Med<|>8)\n##\n(\"relationship\"<|>ROSENSON RS<|>N ENGL J MED<|>Rosenson RS was a researcher in a study published in N Engl J Med<|>8)\n##\n(\"relationship\"<|>REESKAMP LF<|>N ENGL J MED<|>Reeskamp LF was a researcher in a study published in N Engl J Med<|>8)\n##\n(\"relationship\"<|>WITZTUM JL<|>N ENGL J MED<|>Witztum JL was a researcher in a study published in N Engl J Med<|>8)\n##\n(\"relationship\"<|>GAUDET D<|>N ENGL J MED<|>Gaudet D was a researcher in a study published in N Engl J Med<|>8)\n##\n(\"relationship\"<|>FREEDMAN SD<|>N ENGL J MED<|>Freedman SD was a researcher in a study published in N Engl J Med<|>8)\n##\n(\"relationship\"<|>KAUR G<|>AM J PREV CARDIOL<|>Kaur G was a researcher in a study published in Am J Prev Cardiol<|>8)\n##\n(\"relationship\"<|>ABDELRAHMAN K<|>AM J PREV CARDIOL<|>Abdelrahman K was a researcher in a study published in Am J Prev Cardiol<|>8)\n##\n(\"relationship\"<|>BERMAN AN<|>AM J PREV CARDIOL<|>Berman AN was a researcher in a study published in Am J Prev Cardiol<|>8)\n##\n(\"relationship\"<|>BRANDTS J<|>NAT REV CARDIOL<|>Brandts J was a researcher in a study published in Nat Rev Cardiol<|>8)\n##\n(\"relationship\"<|>RAY KK<|>NAT REV CARDIOL<|>Ray KK was a researcher in a study published in Nat Rev Cardiol<|>8)\n##\n(\"relationship\"<|>MUSUNURU K<|>NATURE<|>Musunuru K was a researcher in a study published in Nature<|>8)\n##\n(\"relationship\"<|>CHADWICK AC<|>NATURE<|>Chadwick AC was a researcher in a study published in Nature<|>8)\n##\n(\"relationship\"<|>MIZOGUCHI T<|>NATURE<|>Mizoguchi T was a researcher in a study published in Nature<|>8)\n<|COMPLETE|>"}, {"content": "MANY entities and relationships were missed in the last extraction. Remember to ONLY emit entities that match any of the previously extracted types. Add them below using the same format:\n", "role": "user"}], "parameters": {"model": "deepseek-chat", "frequency_penalty": 0.0, "max_tokens": 4000, "n": 1, "presence_penalty": 0.0, "temperature": 0.0, "top_p": 1.0}}, "key": "chat_extract-continuation-0_c7ff3bc9688d2a4585006fe1761d72d7f2460f79dc30871a6b97ca0fb5c9e3b7_v2"}